Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product...
Transcript of Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product...
![Page 1: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/1.jpg)
Pharma platforms
Initiating a Portfolio Pharma Company
Trans-dermal Approaches
Formuli
Transdermal Spray-On Patch Therapy For CNS Conditions Alternative Options to Improve Outcomes for patients with swallowing difficulties or
poor insight into their condition…
![Page 2: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/2.jpg)
Exis
tin
g O
pp
ort
un
itie
s Overall Summary • A new technology means that low dose therapies can now
be delivered as a ‘spray-patch’ which cannot be felt after 30 seconds.
In CNS Medicine, this has great utility for many types of patients, but mainly those with swallowing difficulties, poor cognition, poor memory, aggression,
hostility, high impulsivity.
• There are many products that can be given through this techology. The main limitation is maximum dose per spray-on patch being 5mg. More than one patch can be sprayed on per dose.
• The pathway to regulatory approval is straightforward and low-cost in the US and Europe utilizing the 505b2 route in the US and the equivalent phase II/III waiver in Europe.
• For low investment, high and fast returns are highly probable.
Formuli
![Page 3: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/3.jpg)
Exis
tin
g O
pp
ort
un
itie
s
Formuli
Market Need Analysis • Chronic Movement Disorders Patients struggle to swallow
(eg. Parkinson’s Disease, Huntington’s Chorea) • Dementia patients struggle to remember their doses and
lack of insight and hostility means they often do not want to take their medication
• Epilepsy Patients can have lack of insight, hostility and may be fitting, so swallowing may be difficult
• Addiction patients may be hostile • Aggression/Hostility in ADHD can make dosing difficult • Aggression/Hostility in Schizophrenia or Mania can make
dosing difficult • Tourette’ Patients may lack insight into their condition and
may be hostile to dosing • Other opportunities may exist for improved convenience
however these are thought to be the best opportunities to improve outcomes and therefore generate higher prices.
![Page 4: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/4.jpg)
Viable Parkinson’s Disease Products: Ropinerole
Pramipexole
Biperiden
Viable Alzheimer’s Disease Products: Memantine Donepezil Rivastigmine Galantamine Viable Anti-Convulsants/Benzos: Diazepam Tiagabine Viable Anti-Addiction/Pain: Bupronorphine + Naloxone Codeine Viable Anti-ADHD Drugs: Methylphenidate Viable Anti-Psychotics: Aripiprazole Olanzapine Risperidone
Product Targets
Formuli
![Page 5: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/5.jpg)
First Targets: Methylphenidate- Feasibility and proof of principal complete
Bupronorphine + Naloxone- Theoretical review and planning complete
Diazepam- Feasibility study complete
Rationale: Reduced Regulatory Hurdles… 505b2 and European late stage waiver decisions are made based on the similarity of the Cmax & AUC data of the two different formulation options. If these are very similar, the waivers on later stage clinical trials are most likely. Existing formulations to be referenced with the transdermal spray-on patch for these molecules with most likelihood of achieving similar Cmax & AUC data are as follows: Diazepam: Suppository Methylphenidate: Traditional Transdermal Patch Bupronorphine + Naloxone: Sublingual melt First stage feasibility data has been generated on transdermal & transbuccal spray-on patch formulations for these molecules and they are viable.
Low Regulatory Hurdle Product Target List
Formuli
![Page 6: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/6.jpg)
First Targets: Ropinerole
Pramipexole
Biperiden
Methylphenidate
Rationale: Reduced Pricing Hurdles… Pricing decisions are made mainly on the basis of levels of unmet need, or ‘real world’ effectiveness. Parkinson’s Disease products are seen as meeting the most unmet need, and methylphenidate is excellent for the hostility seen in childhood ADHD. Other products such as antipsychotics may also meet high unmet need, and full analysis should be made before selecting a priority order of products to develop.
Methylphenidate is the only product to feature on both ‘low’ Regulatory Hurdle and
‘high’ unmet need analysis so may prove the best option to develop first.
Market Need Driven Product Target List
Formuli
![Page 7: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/7.jpg)
MedSpray Methylphenidate
• Comparison of Daytrana with MedSpray
• Equivalent amounts of drug applied (ca.10 mg)
• Release experiment using silicone membrane
• MedSpray can match current marketed product
• MedSpray can enhance or prolong methylphenidate release
• Stability shown at 25 and 40 degrees for T=3 months- could be extrapolated.. Methylphenidate release (n=6, mean, ±SD)
Eg. Methylphenidate data
![Page 8: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/8.jpg)
MedSpray Methylphenidate
Methylphenidate epidermal sheet permeation (n=6, mean, ±SE)
Eg. Methylphenidate data
![Page 9: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/9.jpg)
CEO Mr Russ Pendleton BSc MBA MIoD Runehealthcare, Zysis, Perimeter, Astrazeneca, BASF Pharma, Sanofi 15 years CEO & Managing Director, initiated one medical communications agency, several pharma start-ups. 8 years VP Commercial in small pharma. 14 years Commercial ‘big’ Pharma roles. Successful sales and marketing, fundraising, major product launches, licensing, business development and partnering track record. Responsibilities: Overall Project Management, Commercial Assessments, Marketing Strategy & Deliverables, HE Strategy & Deliverables, Out-licensing & Exit Revenue
Formuli Management – Overall Project Management
Formuli
![Page 10: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/10.jpg)
CEO Dr Andrew Muddle PhD Dr. Andrew Muddle co-founded MedPharm in August 1999. Dr. Muddle has spent 21 years in the pharmaceutical industry in the drug delivery area and has worked for a number of companies of varying sizes. At PowderJect Pharmaceuticals plc, he was Technical Director (Pharmaceutical Development) with responsibility for pharmaceutical sciences, and both pre-clinical and clinical functions. He held this position for three and a half years and made a major contribution in the early development of the company, as well as being pivotal in the IPO in 1997. Dr. Muddle has managed development projects through to commercialisation of several transdermal patch products. Prior to this, he also held technical positions with drug delivery companies such as the Elan Corporation, Ethical Pharmaceuticals Ltd (U.K.), Controlled Therapeutics (Scotland) and Ciba-Geigy (now Novartis). Responsibilities: Generation of the ‘Product’, first stage testing, clinical trial batch supplies.
MedPharm Management
Formuli
![Page 11: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/11.jpg)
CEO
Prof Alan Boyd
30 years’ in pharmaceuticals. Starting with Glaxo Group Research Ltd.
From 1988 head of ICI’s Cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI
Pharma, Canada. In 1995, became Head of Medical Research for Zeneca Pharmaceuticals.
In 1999 became Director of Research and Development for Ark Therapeutics Ltd responsible for delivering the majority of key
development milestones that have shaped the company. In particular the development of the gene based medicines portfolio.
In 2005, initiated Boyd Consultants. The focus of which is to aid and support early stage life-science based companies and groups in
Universities who have medicine based R&D projects. Clients now include many organisations and companies in Europe, North
America and Japan who are devoted to the development of medicines.
A graduate in Biochemistry and Medicine from the University of Birmingham, UK, a Fellow, Board Member and Chair of the Specialist
Advisory Committee in Pharmaceutical Medicine at the Faculty of Pharmaceutical Medicine, Royal College of Physicians, United
Kingdom. Elected Vice-President of the Faculty in November 2012.
In November 2009 appointed an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham
Medical School, in recognition of his expertise in medicines development.
Responsibilities: Global Medical Director Role, including steering Clinical Trial activity and Regulatory Affairs to generate sufficient
data to ensure FDA/EMA approvals. Supporting Out-licensing activities.
Boyd Consultancy Management
Formuli
![Page 12: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/12.jpg)
Pharma platforms
Introducing
The Development
Path for Each Product
Formuli
![Page 13: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/13.jpg)
• Executive Summary • RoI Analysis • Target Product Profile • Market Need, Size & Dynamics • Project Plan • Formulation Work • Clinical Work • Marketing & Health Economic Considerations • Interested Companies for Exit
Creating a TD CNS Product
Formuli
![Page 14: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/14.jpg)
Executive Summary • To develop a transdermal formulation of a target molecule for treatment of the
target condition. • A quick and straightforward route to approval using the 505b2 phase II/III waiver
route. • This is only achievable in the EU and US. • Phase III trials are required for other markets.
• Overall cost to NDA Submission of USD 3 M per product/technology combination • Overall cost to market (including commercialisation and HE/QoL package) of USD
5-8 M per product/technology combination. • Around USD 3 M to get through NDA submission. • Further HE/QoL costs are recommended in the order of USD 1-3 M depending on
quality of outcome data desired.
• Intellectual Property Protection • Trandermal (and Transbuccal) technologies have global patent protection to 2028. • Data exclusivity protection will apply.
• LCM & Fallback strategies • Many molecules can be dosed in this way
• Exit • Onward sale or outsourced commercialization
Formuli
![Page 15: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/15.jpg)
Return on Investment Analysis per product 1. Cost of Development USD 3 M 2. Cost of HE/QoL Study eg. USD 1-3 M 3. Cost of Launch eg. USD 2 M
Overall Cost USD 5-7 M by end 2018 Returns: 1. Assuming PYS Forecast USD 250-300 M in 2028 2. NPV (12%) USD 51 M at 2015 2. rNPV (20% of NPV) USD 10 M at 2015
Formuli Completing Product Potential
![Page 16: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/16.jpg)
Target Product Profile (TPP)
• Transdermal Spray Formulation of Target Compound
– ‘Patch in a Can’ spray adhesive plus drug diameter of 1.5-2cm.
– Bonds to Skin, no sensation of substance felt to patient once dry (30secs), invisible
– No irritation.
– Dose Delivered over 4-5 hours
• Dose delivered without the need to swallow
• Other benefits can follow eg. for Biperiden, further gut interaction with L-DOPA is by-passed thus combination therapy with L-DOPA for Biperiden is now achievable.
Contact: Russ Pendleton +44 7878 201 416 [email protected]
Formuli
![Page 17: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/17.jpg)
Project Plan per product
Formuli Completing Product Potential
2016 Feasibility Testing Cost: USD 70K per product
2016-17 Perform pK Bridging Study for NDA Submission
Cost: USD 2.45 M
2017-18 Perform HE/QoL Patient Preference Study
Eg. Cost: USD 1-3 M
2018 Commercialisation Eg. Cost: USD 2 M
2016 Reformulate to TD/TB Cost: USD 230
2016 Prepare Clinical Supplies Cost: USD 250
![Page 18: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/18.jpg)
Formulation Work (1)
Formuli
• Transparent Patch in a Can® – invisible
• Drug presented in a high thermodynamic state
o Enhanced drug delivery
• Self assembling
• Variable dosage forms
o Gel-film, water resistance, adherence, retention, viscosity, thickness
• Versatile
• Cost effective and safe components
• Already taken beyond Phase II
• Dermal or buccal/sublingual delivery route
MedSpray®
![Page 19: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/19.jpg)
Skin
Surface
Formulation Work (2)
Formuli
MedSpray
Propellant dissipates before touching skin surface,
increase of drug concentration in solution
Saturated solution of
drug
Gel/film of drug,
solvents and
polymer
Evaporation of volatile
solvent, continued
increase of drug
concentration and thus
thermodynamic activity
![Page 20: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/20.jpg)
Formulation Work (3)
Formuli
MedRo®
• MedSpray for the mouth
o Application to different oral mucosal regions, sub-lingual or
buccal
o Direct access to the systemic circulation
o Fast onset of action
o Mucoadhesive excipients improve formulation retention for
prolonged/sustained delivery
• Extensive scope for targeting a large number of conditions
using this technology to re-juvenate many molecules
![Page 21: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/21.jpg)
Clinical Study Work
• pK Bridging Study
– Eg. 1mg & 2mg are usual daily doses
– Four arm study • 1mg OD tablet
• 2mg OD tablet
• 1mg TB spray
• 2mg TB spray
– Repeat dose study for 7 days
– Measure – drug blood levels
• Sample Size – 10 Patients per study arm
• Compare blood levels of standard formulation with TD Spray utilizing FDA 1998 guidelines on well-categorized drugs, and 505b2 approval process
• Regulatory Costs included plus visits to EMA & FDA
• Anticipated Cost: USD 3 M
Contact: Russ Pendleton +44 7878 201 416 [email protected]
Formuli
![Page 22: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/22.jpg)
Eg. Market Research & Health Economics
Formuli Achieving Successful Launch
Preparation of Marketing Materials including:
****
Product Profiling Branding Detailing
Advertising Med Comms Conference Plan
Publications Planning Ambassador Training &
Outreach Packaging
Refined Forecasting Salesforce Training
Cost: USD 1.3 M
Preparation of HE Materials including:
****
Outcomes Research Markov Price Modelling Budgetary Impact Model
Market Access Strategy Analysis Value Proposition
Cost: USD 700 K
![Page 23: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/23.jpg)
Interested Companies
• Exit Revenue is generated through onward licensing.
• Negotiations to be ongoing throughout the project, however target transaction timing is around the point of NDA Submission.
• Interested Companies to date are:
– Europe • 3 companies
– US • 3 companies
– MENA Region • 2 companies
– China • 2 companies
– Korea • 2 companies
– Turkey & Eastern Europe/Asia • 2 companies
Contact: Russ Pendleton +44 7878 201 416 [email protected]
Formuli
![Page 24: Pharma platforms - Bio-Lynx · 2017-09-22 · 2016 Feasibility Testing Cost: USD 70K per product 2016-17 Perform pK Bridging Study for NDA Submission Cost: USD 2.45 M 2017-18 Perform](https://reader033.fdocuments.in/reader033/viewer/2022050103/5f4222ad14f18817b70c8968/html5/thumbnails/24.jpg)
Finding the Global Solution
Contact: Russ Pendleton
+44 7878 201 416 [email protected]
Gain the most from every product – Partner with Formuli